Approval · Notice of Compliance 20265 · 2018
XIAFLEX: Notice of Compliance 20265
Issued January 2, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20265
- Date
- January 2, 2018
- Company
- Endo Ventures Ltd
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: for the treatment of adult men with peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapie
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| XIAFLEX | Not yet assigned | — |
Medicinal ingredients
- COLLAGENASE CLOSTRIDIUM HISTOLYTICUM 0.9 MG per VIAL